[Clinical Efficacy of Recombinant Human Thrombomodulin for Surgical Patients with Disseminated Intravascular Coagulation Associated with Oncologic Emergency].

Autor:	Ikuta L; Dept. of Surgery, Meiwa Hospital., Nakajima T, Fujikawa M, Nomura K, Matsuki G, Ichise N, Kasai M, Okamoto R, Ikuta S, Nakamoto Y, Aihara T, Yanagi H, Yamanaka N
Jazyk:	japonština
Zdroj:	Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2022 Dec; Vol. 49 (13), pp. 1408-1410.
Abstrakt:	Aim: We evaluated the clinical efficacy of recombinant human thrombomodulin(rTM)for surgical patients with disseminated intravascular coagulation syndrome(DIC)associated with an oncologic emergency(OE). Subjects and Methods: Thirteen patients who underwent surgery for OE complicated with DIC and were treated with rTM in our institution were evaluated. We retrospectively analyzed the clinical changes of parameters in white blood cell count(WBC), platelet count, CRP, PT-INR and DIC scores after the rTM treatment. Results: The average length of the days using rTM was 4.7 for 12 patients, excluding one who died within 30 days after surgery. Nine of 12 patients(75%)had DIC scores of less than 3 after the rTM treatment. WBC tended to decrease after the rTM treatment, without statistical difference. However, CRP, platelet count, PT-INR and DIC scores were significantly improved after the rTM treatment(p<0.05). Conclusions: rTM may be useful in the treatment of DIC for surgical OE patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu